Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
IDN-6556-17 Study Investigators
Internal Medicine
Int Med - Digestv & Liver Dis
Research output
:
Contribution to journal
›
Article
›
peer-review
35
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
100%
Fibrosis
36%
End Stage Liver Disease
19%
Fatty Liver
17%
Placebos
11%
Liver
8%
Study Guides
7%
Hepatorenal Syndrome
7%
Portal Pressure
7%
Caspase Inhibitors
6%
Carbon Tetrachloride
6%
Hepatic Encephalopathy
6%
International Normalized Ratio
6%
Portal Hypertension
5%
Peritonitis
5%
Serum Albumin
5%
Diuretics
5%
Ascites
5%
Double-Blind Method
5%
Bilirubin
5%
Sodium
4%
Hepatocellular Carcinoma
4%
Clinical Trials
3%
Hemorrhage
3%
Apoptosis
3%
Inflammation
3%
Mortality
2%
Therapeutics
2%
Wounds and Injuries
2%
Child
2%